GLUE (Monte Rosa Therapeutics) DeferredTaxAndRevenue: $22.10 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GLUE Monte Rosa Therapeutics Inc GLUE
27 GF Score
Price $14.32
! 4 Warning Signs
View Full Analysis

What is Monte Rosa Therapeutics DeferredTaxAndRevenue?

Monte Rosa Therapeutics GLUE -0.52% 27 DeferredTaxAndRevenue is $22.10 Mil as of Jun. 2026. GuruFocus rates GLUE with a GF Score™ of 27/100. The stock has 4 warning signs investors should review.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Monte Rosa Therapeutics's current deferred tax and revenue for the quarter that ended in Jun. 2026 was $22.10 Mil.

Monte Rosa Therapeutics DeferredTaxAndRevenue Related Terms

Monte Rosa Therapeutics DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Monte Rosa Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monte Rosa Therapeutics DeferredTaxAndRevenue Chart

Monte Rosa Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
DeferredTaxAndRevenue
Get a 7-Day Free Trial 0.00 0.00 17.68 117.23 29.57

Monte Rosa Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.41 24.79 29.57 33.06 22.10
GLUE
27GF Score
Monte Rosa Therapeutics Inc GLUE
DeferredTaxAndRevenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of $22.10 Mil mean?
Monte Rosa Therapeutics (GLUE) has a DeferredTaxAndRevenue of $22.10 Mil as of Jun. 2026. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Monte Rosa Therapeutics.
Is Monte Rosa Therapeutics' DeferredTaxAndRevenue too high?
Monte Rosa Therapeutics' current DeferredTaxAndRevenue is $22.10 Mil. Overall, Monte Rosa Therapeutics has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Monte Rosa Therapeutics' DeferredTaxAndRevenue compare to PGEN and ZBIO?
Monte Rosa Therapeutics' DeferredTaxAndRevenue of $22.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Monte Rosa Therapeutics. Monte Rosa Therapeutics's current DeferredTaxAndRevenue is $22.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monte Rosa Therapeutics stock overvalued right now?
Monte Rosa Therapeutics (GLUE) has a current DeferredTaxAndRevenue of $22.10 Mil. The current DeferredTaxAndRevenue is $22.10 Mil. Monte Rosa Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Monte Rosa Therapeutics (GLUE), the current DeferredTaxAndRevenue is $22.10 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monte Rosa Therapeutics Business Description

Address 321 Harrison Avenue, Suite 900, Boston, MA, USA, 02118
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
27GF Score

Get the complete analysis for GLUE

DeferredTaxAndRevenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.32
Price